psilocybin has been researched along with Anxiety in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (5.56) | 29.6817 |
| 2010's | 14 (25.93) | 24.3611 |
| 2020's | 35 (64.81) | 2.80 |
| Authors | Studies |
|---|---|
| Lehto, RH; Miller, M; Sender, J | 1 |
| Bogadi, M; Kaštelan, S | 1 |
| Bourzat, F; Harvey, K; Kryskow, P; Kuypers, KPC; Polito, V; Rootman, JM; Santos-Brault, E; Stamets, P; Walsh, Z | 1 |
| Breeksema, JJ; Schimmers, N; Schoevers, RA; Smith-Apeldoorn, SY; van den Brink, W; Veraart, J | 1 |
| Fejer, G; Hajkova, K; Kuchar, M; Lempe, P; Marschall, J; Prochazkova, L; van Elk, M | 1 |
| Beaussant, Y; Garcia, ACM; Maia, LO | 1 |
| Ameringen, MV; Beaulieu, S; Castle, D; Frey, BN; Garel, N; Greenway, KT; Husain, MI; Kennedy, SH; Lam, RW; Lee, Y; Mansur, RB; McIntyre, RS; Milev, R; Offman, H; Parikh, SV; Ravindran, AV; Rosenblat, JD; Schaffer, A; Taylor, V; Tourjman, V; Yatham, LN | 1 |
| Calder, AE; Hasler, G | 1 |
| Dalo, J; Weisman, N; White, CM | 1 |
| Aaronson, ST; Kirlic, N; Lennard-Jones, M; Miller, TM; Modlin, NL; Rucker, JJ; Schlosser, D | 1 |
| Aaronson, ST; Alvarez, O; Atli, M; Bennett, JC; Croal, M; DeBattista, C; Dunlop, BW; Feifel, D; Goodwin, GM; Hellerstein, DJ; Husain, MI; Kelly, JR; Lennard-Jones, MR; Licht, RW; Malievskaia, E; Marwood, L; Mistry, S; Páleníček, T; Redjep, O; Repantis, D; Schoevers, RA; Septimus, B; Simmons, HJ; Soares, JC; Somers, M; Stansfield, SC; Stuart, JR; Tadley, HH; Thiara, NK; Tsai, J; Wahba, M; Williams, S; Winzer, RI; Young, AH; Young, MB; Zisook, S | 1 |
| Garza, G; Moghaddam, B; Olson, RJ; Torrado Pacheco, A | 1 |
| Carhart-Harris, RL; Monson, CM; Wagner, AC; Zeifman, RJ | 1 |
| Belouin, SJ; Heal, DJ; Henningfield, JE; Smith, SL | 1 |
| Ezeaka, UC; Kim, HJJ; Laprairie, RB | 1 |
| Amit, M; Cohen, L; Ramondetta, LM; Yaniv, D | 1 |
| Aaronson, ST; Alexander, JL; Baron, DA; Garakani, A; Gross, LS; Pine, JH; Raison, CL; Sumner, CR | 1 |
| Gerlai, R; Syed, OA; Tsang, B | 1 |
| Aguilar-Valles, A; Benetatos, J; Bonniwell, EM; Cameron, LP; Castrén, E; Jaster, AM; Lewis, V; McCorvy, JD; Moliner, R; Palner, M | 1 |
| Boudreau, E; Orlowski, K | 1 |
| Jachimowski, A; Kucia, K | 1 |
| Babiker, M; Baker, A; Brennan, C; Burke, L; Kelly, JR; O'Keane, V | 1 |
| Germann, CB | 1 |
| Amada, N; Jungaberle, H; Klein, M; Lea, T; Schecke, H | 1 |
| Goldberg, SB; Hutson, PR; Nicholas, CR; Pace, BT; Raison, CL | 1 |
| Chi, T; Gold, JA | 1 |
| Aday, JS; Bloesch, EK; Davis, AK; Davoli, CC; Mitzkovitz, CM | 1 |
| Jones, TK; Lippmann, S | 1 |
| Balaet, M; Buchborn, T; Carhart-Harris, RL; Erritzoe, D; Kaertner, LS; Kettner, H; Roseman, L; Spriggs, MJ; Steinborn, MB; Timmermann, C | 1 |
| Benyamina, A; Hermand, M; Karila, L; Pétillion, A; Romeo, B | 1 |
| Jordan, I | 1 |
| Bei, B; Wiley, JF | 1 |
| Hieronymus, F; Østergaard, SD | 1 |
| Gründer, G; Mertens, L | 1 |
| Blemings, A; Carhart-Harris, R; Nutt, DJ | 1 |
| Bayat, M | 1 |
| Johnson, MI; Whelan, A | 1 |
| Flanagan, TW; Nichols, CD | 1 |
| Ross, S | 1 |
| Andreassen, OA; Kvam, TM; Stewart, LH | 1 |
| Anderson, T; Dinh-Williams, LA; Farb, NAS; Hapke, E; Hui, K; Petranker, R; Rosenbaum, D; Weissman, CR | 1 |
| Anderson, T; Christopher, A; Dinh-Williams, LA; Hapke, E; Hui, K; Petranker, R; Rosenbaum, D; Weissman, C | 1 |
| Barrett, FS; Bradstreet, MP; Griffiths, RR; Johnson, MW; Leoutsakos, JS | 1 |
| Nutt, D | 1 |
| Agin-Liebes, G; Babb, J; Belser, A; Bossis, A; Cohen, B; Corby, P; Guss, J; Kalliontzi, K; Malone, T; Mennenga, SE; Ross, S; Schmidt, BL; Su, Z | 1 |
| Carducci, MA; Cosimano, MP; Griffiths, RR; Johnson, MW; Klinedinst, MA; Richards, BD; Richards, WA; Umbricht, A | 1 |
| McCorvy, JD; Olsen, RH; Roth, BL | 1 |
| Johnson, MW; Nichols, CD; Nichols, DE | 1 |
| Stix, G | 1 |
| Chopra, GS; Danforth, AL; Greer, GR; Grob, CS; Hagerty, M; Halberstadt, AL; McKay, CR | 1 |
| Check, E | 1 |
| Abadie, P; Dollfus, S; Espiard, ML; Halbecq, I; Lecardeur, L | 1 |
| Benjamin, C | 1 |
| Kochansky, GE; Lieff, J; Salzman, C; Shader, RI | 1 |
20 review(s) available for psilocybin and Anxiety
| Article | Year |
|---|---|
The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research.
Topics: Anxiety; Humans; Mental Health; Neoplasms; Psilocybin; Psychotherapy | 2022 |
Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.
Topics: Anxiety; Depression; Hallucinogens; Humans; Psilocybin; Quality of Life | 2022 |
The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review.
Topics: Anxiety; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin | 2022 |
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
Topics: Anxiety; Canada; Depressive Disorder, Major; Hallucinogens; Humans; Neoplasms; Psilocybin | 2023 |
Towards an understanding of psychedelic-induced neuroplasticity.
Topics: Anxiety; Anxiety Disorders; Hallucinogens; Humans; Neuronal Plasticity; Psilocybin | 2023 |
Psychedelics for Patients With Cancer: A Comprehensive Literature Review.
Topics: Antidepressive Agents; Anxiety; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Neoplasms; Psilocybin; Randomized Controlled Trials as Topic | 2023 |
Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
Topics: Anxiety; Female; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Psilocybin; Substance-Related Disorders | 2023 |
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.
Topics: Anxiety; Anxiety Disorders; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin | 2023 |
The zebrafish for preclinical psilocybin research.
Topics: Animals; Anxiety; Anxiety Disorders; Hallucinogens; Psilocybin; Zebrafish | 2023 |
Beyond the 5-HT
Topics: Anxiety; Hallucinogens; Humans; Psilocybin; Receptor, Serotonin, 5-HT2A; Serotonin | 2023 |
Classical psychedelics in psychiatry - renaissance of interest and therapeutic perspectives.
Topics: Anxiety; Hallucinogens; Humans; Mental Health; Psilocybin; Psychiatry | 2023 |
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.
Topics: Anxiety; Depression; Female; Humans; Male; Psilocybin; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.
Topics: Animals; Anxiety; Hallucinogens; Humans; Pharmaceutical Preparations; Psilocybin; Substance-Related Disorders | 2020 |
Long-term effects of psychedelic drugs: A systematic review.
Topics: Anxiety; Emotions; Hallucinogens; Humans; Pharmaceutical Preparations; Psilocybin | 2020 |
Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review.
Topics: Anxiety; Anxiety Disorders; Behavior, Addictive; Hallucinogens; Humans; Psilocybin | 2021 |
[Classic psychedelic drugs and their potential therapeutic effect].
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Cluster Headache; Depression; Hallucinogens; Humans; Lysergic Acid Diethylamide; Obsessive-Compulsive Disorder; Psilocybin; Receptor, Serotonin, 5-HT2A; Substance-Related Disorders | 2017 |
Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?
Topics: Anxiety; Chronic Pain; Depression; Humans; Lysergic Acid Diethylamide; Pain; Psilocybin; Serotonin Receptor Agonists; Treatment Outcome | 2018 |
Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.
Topics: Anxiety; Depression; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neoplasms; Psilocybin; Serotonin Antagonists; Stress, Psychological | 2018 |
Psychedelic drugs in the treatment of anxiety, depression and addiction.
Topics: Anxiety; Anxiety Disorders; Depression; Depressive Disorder; Hallucinogens; Humans; Lysergic Acid Diethylamide; Obsessive-Compulsive Disorder; Psilocybin; Substance-Related Disorders | 2018 |
Psychedelics as Medicines: An Emerging New Paradigm.
Topics: Anxiety; Brain; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Hallucinogens; Humans; Inflammation; Inflammation Mediators; Lysergic Acid Diethylamide; Mental Disorders; Mind-Body Therapies; Obsessive-Compulsive Disorder; Psilocybin; Psychotherapy; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Severity of Illness Index; Substance-Related Disorders | 2017 |
7 trial(s) available for psilocybin and Anxiety
| Article | Year |
|---|---|
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.
Topics: Adult; Anxiety; Cross-Over Studies; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Emotions; Female; Hallucinogens; Humans; Male; Middle Aged; Psilocybin; Surveys and Questionnaires; Young Adult | 2022 |
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
Topics: Anxiety; Depression; Depressive Disorder, Major; Humans; Patient Reported Outcome Measures; Psilocybin; Quality of Life | 2023 |
How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.
Topics: Anxiety; Anxiety Disorders; Depressive Disorder, Major; Humans; Psilocybin; Treatment Outcome | 2023 |
The psychedelic renaissance: the next trip for psychiatry?
Topics: Anxiety; Double-Blind Method; Hallucinogens; Humans; Psilocybin; Psychiatry; Quality of Life | 2022 |
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Topics: Adult; Aged; Anxiety; Cross-Over Studies; Depression; Double-Blind Method; Female; Hallucinogens; Humans; Male; Middle Aged; Neoplasms; Psilocybin; Psychotherapy; Quality of Life; Surveys and Questionnaires; Young Adult | 2016 |
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Topics: Anxiety; Attitude; Cross-Over Studies; Depression; Double-Blind Method; Female; Follow-Up Studies; Hallucinogens; Humans; Male; Middle Aged; Neoplasms; Psilocybin; Quality of Life; Surveys and Questionnaires | 2016 |
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Topics: Adult; Affect; Anxiety; Double-Blind Method; Female; Follow-Up Studies; Hallucinogens; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Personality Inventory; Pilot Projects; Psilocybin; Time Factors; Treatment Outcome | 2011 |
27 other study(ies) available for psilocybin and Anxiety
| Article | Year |
|---|---|
A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents.
Topics: Adolescent; Anxiety; Humans; Personality; Psilocybin | 2021 |
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.
Topics: Adolescent; Adult; Anxiety; Cognition; Cross-Sectional Studies; Depression; Female; Hallucinogens; Humans; International Cooperation; Lysergic Acid Diethylamide; Male; Mental Health; Middle Aged; Motivation; Psilocybin; Surveys and Questionnaires; Young Adult | 2021 |
Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.
Topics: Anxiety; Depressive Disorder, Major; Hallucinogens; Humans; Obsessive-Compulsive Disorder; Psilocybin | 2023 |
Acute psilocybin enhances cognitive flexibility in rats.
Topics: Animals; Anxiety; Cognition; Female; Hallucinogens; Ketanserin; Male; Psilocybin; Rats; Serotonin; Serotonin 5-HT2 Receptor Antagonists | 2023 |
Psychedelics: Threshold of a Therapeutic Revolution.
Topics: Anxiety; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Substance-Related Disorders | 2023 |
Psilocybin-assisted psychotherapy for cancer-related anxiety and depression.
Topics: Anxiety; Depression; Humans; Neoplasms; Psilocybin; Psychotherapy | 2023 |
Psilocybin therapy to reduce depression following a terminal diagnosis.
Topics: Anxiety; Depression; Humans; Psilocybin | 2023 |
The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging.
Topics: Aging; Aging, Premature; Animals; Anxiety; Brain-Derived Neurotrophic Factor; Consciousness; Depression; Disease Models, Animal; DNA Methylation; Endocrine System; Humans; Models, Genetic; Models, Psychological; Neurotransmitter Agents; Oxidative Stress; Personality; Psilocybin; Psychotropic Drugs; Research Design; Serotonin Plasma Membrane Transport Proteins; Stress, Psychological; Telomere Shortening | 2020 |
Microdosing psychedelics: Motivations, subjective effects and harm reduction.
Topics: Adult; Anxiety; Depression; Dose-Response Relationship, Drug; Female; Hallucinogens; Harm Reduction; Humans; Lysergic Acid Diethylamide; Male; Mental Health; Middle Aged; Motivation; Psilocybin; Substance-Related Disorders; Surveys and Questionnaires; Young Adult | 2020 |
Psilocybin Can Diminish Depression.
Topics: Anxiety; Depression; Hallucinogens; Humans; Psilocybin | 2020 |
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing.
Topics: Adult; Affect; Anxiety; Dose-Response Relationship, Drug; Emotions; Female; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Mental Health; Middle Aged; Motivation; Outcome Assessment, Health Care; Placebo Effect; Psilocybin; Quality of Life | 2021 |
Psilocybin for Depression.
Topics: Anxiety; Depression; Humans; Psilocybin | 2021 |
Psilocybin for Depression.
Topics: Anxiety; Depression; Humans; Psilocybin | 2021 |
Psilocybin for Depression.
Topics: Anxiety; Depression; Humans; Psilocybin | 2021 |
Psilocybin for Depression.
Topics: Anxiety; Depression; Humans; Psilocybin | 2021 |
Psilocybin for Depression. Reply.
Topics: Anxiety; Depression; Humans; Psilocybin | 2021 |
Psychedelics as anti-inflammatory agents.
Topics: Amphetamines; Animals; Anti-Inflammatory Agents; Anxiety; Behavior, Animal; Depression; Hallucinogens; Humans; Obsessive-Compulsive Disorder; Psilocybin; Receptor, Serotonin, 5-HT2A | 2018 |
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
Topics: Adult; Anxiety; Creativity; Depression; Dose-Response Relationship, Drug; Emotions; Female; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Mental Health; Perception; Personality; Psilocybin; Surveys and Questionnaires | 2019 |
Psychedelic microdosing benefits and challenges: an empirical codebook.
Topics: Adolescent; Adult; Affect; Anxiety; Arousal; Attention; Clinical Trials, Phase I as Topic; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Grounded Theory; Guideline Adherence; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Middle Aged; Psilocybin; Retrospective Studies; Risk Assessment | 2019 |
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.
Topics: Adult; Affect; Agaricales; Anxiety; Depression; Emotions; Female; Hallucinogens; Humans; Male; Psilocybin; Surveys and Questionnaires | 2016 |
Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future.
Topics: Anxiety; Depression; Hallucinogens; Humans; Neoplasms; Psilocybin | 2016 |
Psilocybin for depression and anxiety associated with life-threatening illnesses.
Topics: Anxiety; Depression; Depressive Disorder; Hallucinogens; Humans; Psilocybin | 2016 |
Return of a problem child.
Topics: Anxiety; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neoplasms; Psilocybin | 2009 |
Psychedelic drugs: the ups and downs of ecstasy.
Topics: Agaricales; Animals; Anxiety; Brain; Cactaceae; Controlled Clinical Trials as Topic; Female; Hallucinogens; History, 20th Century; History, 21st Century; Humans; Lysergic Acid Diethylamide; Medicine, Traditional; Mescaline; N-Methyl-3,4-methylenedioxyamphetamine; Phytotherapy; Pilot Projects; Psilocybin; Psychotherapy; Stress Disorders, Post-Traumatic | 2004 |
Hallucinogen persisting perception disorder after psilocybin consumption: a case study.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Anxiety; Depressive Disorder; Diagnosis, Differential; Hallucinogens; Humans; Male; Marijuana Smoking; Perceptual Disorders; Psilocybin; Psychiatric Status Rating Scales; Recurrence; Risperidone; Sertraline; Social Behavior Disorders; Time Factors | 2005 |
Persistent psychiatric symptoms after eating psilocybin mushrooms.
Topics: Adult; Anxiety; Basidiomycota; Humans; Jurisprudence; Lorazepam; Male; Psilocybin | 1979 |
The psychology of hallucinogenic drug discontinuers.
Topics: Adult; Anxiety; Depression; Female; Gambling; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Mental Disorders; Mescaline; MMPI; Personality; Psilocybin; Psychological Tests; Substance-Related Disorders | 1972 |